Welcome to our dedicated page for Alterity Therapeutics news (Ticker: ATHE), a resource for investors and traders seeking the latest updates and insights on Alterity Therapeutics stock.
Alterity Therapeutics Limited (symbol: ATHE) is a pioneering biopharmaceutical company based in Melbourne, Australia, focused on developing therapeutic drugs for neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Huntington's disease, and multiple system atrophy. Founded in 1997 and originally known as Prana Biotechnology Limited, the company rebranded to Alterity Therapeutics Limited in April 2019.
The company’s flagship drug candidate, ATH434, has successfully completed Phase I clinical trials and is geared towards treating Parkinson's disease and other associated movement disorders. The drug has shown promise in clinical evaluations to slow disease progression, thus improving the quality of life for patients.
Alterity is also advancing PBT2, another leading drug candidate, originally designed as an antimicrobial agent but repurposed for treating Alzheimer's and Huntington's diseases. PBT2 has garnered attention owing to its potential to tackle the cognitive decline associated with these debilitating conditions.
Alterity Therapeutics is actively engaged in multiple research collaborations and partnerships with academic institutions and pharmaceutical companies to enhance its drug development pipeline. Their multi-faceted approach to addressing neurodegenerative disorders underscores the company's commitment to innovation and patient care.
Recent achievements include a collaborative study titled “A multimodal approach for diagnosis of early Multiple System Atrophy,” presented at the MDS 2023 conference, demonstrating the company's dedication to advancing scientific understanding and treatment methodologies.
Financially, Alterity Therapeutics maintains a stable condition, actively investing in research and development to push forward its clinical programs. The company's strategic initiatives and ongoing projects highlight its pivotal role in the healthcare domain, with a focus on creating significant therapeutic advancements.
For investors and stakeholders, Alterity Therapeutics represents a compelling opportunity in the biopharmaceutical sector, with a clear focus on addressing unmet medical needs through innovative drug discovery and development.
Alterity Therapeutics (NASDAQ: ATHE) presented new data on ATH434 at the Society for Neuroscience 2024 in Chicago. The poster, titled 'Potent Antioxidant and Mitochondrial-protectant Effects of ATH434, a Novel Inhibitor of α-Synuclein Aggregation with Moderate Iron-binding Affinity,' showcased ATH434's neuroprotective and mitochondrial protectant properties, including reducing lipid damage in two neuronal injury models.
The study, led by Dr. Daniel J. Kosman at SUNY Buffalo, demonstrated ATH434's intrinsic antioxidant activity and its ability to redistribute excess labile iron. These properties suggest potential for treating neurodegenerative diseases like Parkinson's. ATH434 also promoted energy production in mitochondria through a pathway less prone to causing oxidative stress in unstressed cells.
Dr. David Stamler, CEO of Alterity, emphasized the importance of these findings in understanding ATH434's potential as a disease-modifying treatment for neurodegenerative disorders.
Alterity Therapeutics (NASDAQ: ATHE) presented multiple data sets at the International Congress of Parkinson's Disease and Movement Disorders®, highlighting the potential of ATH434 as a disease-modifying therapy for Multiple System Atrophy (MSA). Key findings include:
1. In the ATH434-202 Phase 2 open-label trial, 30% of participants showed stable or improved clinical outcomes.
2. Clinical responders demonstrated stability in brain iron levels and neurofilament light chain (NfL) levels, suggesting potential to slow neurodegeneration.
3. ATH434 exhibited a favorable safety profile with no drug-related serious adverse events.
4. The ATH434-201 randomized, double-blind Phase 2 trial baseline data was presented, focusing on early-stage MSA patients.
5. Preclinical data in Parkinson's disease models showed ATH434 reduced brain iron levels and improved motor performance.
Topline data from ATH434-201 is expected in January 2025, with 12-month data from ATH434-202 later in the year.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), a biotechnology company focused on developing treatments for neurodegenerative diseases, has appointed Abby Macnish Niven as its new Chief Financial Officer (CFO), effective immediately. CEO David Stamler expressed confidence in Ms Macnish Niven's broad experience and financial background to help advance the company's programs.
Ms Macnish Niven brings extensive experience in private wealth management from groups including ANZ, UBS, and Ord Minett. She also consults for various listed and unlisted companies in governance, finance, and corporate structure. She holds Bachelor of Commerce and Bachelor of Science degrees from the University of Western Australia and is a Chartered Finance Analyst.
Ms Macnish Niven replaces Mr Phillip Hains, who served as CFO since December 2023. Mr Hains will continue as Company Secretary.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced multiple presentations at the International Congress of Parkinson's Disease and Movement Disorders® (MDS) from September 27 to October 1, 2024, in Philadelphia. Highlights include:
1. A late-breaking oral presentation and poster on interim data from the ATH434-202 trial in advanced multiple system atrophy (MSA).
2. An oral presentation and poster on ATH434-201 Phase 2 baseline characteristics.
3. Two additional poster presentations on:
- Association between clinical progression in MSA and brain volume changes
- Effects of ATH434 in a Parkinson's disease model in macaques
These presentations showcase Alterity's progress in developing treatments for neurodegenerative diseases, particularly focusing on their ATH434 compound for MSA and Parkinson's disease.
Alterity Therapeutics (NASDAQ: ATHE) released its Q4 FY24 Quarterly Cash Flow Report, highlighting positive interim data from the ATH434-202 Phase 2 clinical trial for Multiple System Atrophy (MSA). The trial showed improvement in daily living activities and stable or improved neurological symptoms in some patients. The bioMUSE Natural History Study continues to inform Alterity's Phase 2 trials, characterizing early-stage MSA.
Key points:
- Cash balance of A$12.6M as of June 30, 2024
- Positive interim data from ATH434-202 Phase 2 trial
- Ongoing ATH434-201 Phase 2 trial for early-stage MSA
- Presentations at World Orphan Drug Congress and American Academy of Neurology Annual Meeting
- Promising results from bioMUSE study guiding patient selection and endpoints for Phase 2 trials
Alterity Therapeutics (NASDAQ: ATHE), a biotechnology company focused on developing treatments for neurodegenerative diseases, has announced an upcoming investor webinar. The event, hosted by MST Financial, is scheduled for July 25, 2024, at 8:30 AM AEST (July 24, 2024, at 6:30 PM ET).
CEO David Stamler will present recent company developments, including interim data from the Phase 2 open-label study of ATH-434 (202). Investors and shareholders can register for the Zoom webcast and will have the opportunity to ask questions following the presentation.
This webinar provides a platform for Alterity to share its progress in developing disease-modifying treatments and engage with its investor community.
Alterity Therapeutics (NASDAQ: ATHE) has reported positive interim data from its ATH434-202 Phase 2 clinical trial for multiple system atrophy (MSA). Key findings include:
- 43% of participants showed improvement in daily living activities
- 29% had stable or improved neurological symptoms
- Objective biomarkers demonstrated improvement consistent with clinical findings
- ATH434 was well-tolerated with no safety signals detected
The interim analysis included data from 7 participants treated for 6 months and neuroimaging data from 3 participants treated for 12 months. Clinical responders showed reduced iron accumulation in key brain areas and stable levels of NFL, a marker of axonal injury. These results suggest ATH434's potential to modify the course of MSA, particularly in less advanced cases.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) will present at the MST Access ‘Hidden Gems in Life Sciences’ webinar. The presentation, led by CEO David Stamler, will provide an overview of the company's initiatives in developing treatments for neurodegenerative diseases. The webinar will take place on June 13, 2024, in Australia (1:30 p.m. AEST) and June 12, 2024, in the United States (8:30 p.m. PT/11:30 p.m. ET). Investors can register to join the presentation and ask questions during the event. A recording will be available on Alterity's website post-event.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) will host an investor webcast to discuss new data from the bioMUSE Natural History Study and its implications for the ATH434-202 Phase 2 trial endpoints. The webcast, set for May 29, 2024, in the U.S. and May 30, 2024, in Australia, will feature CEO Dr. David Stamler and Professor Daniel Claassen from Vanderbilt University. Dr. Claassen, a key opinion leader and principal investigator, will provide insights into the study results and their impact. Registration is required to attend the webcast, where investors can ask questions.
Alterity Therapeutics, a biotechnology company, received positive feedback from the Data Monitoring Committee regarding the Phase 2 clinical trial of ATH434 for the treatment of multiple system atrophy (MSA). The trial is progressing as planned, with top-line data expected in January 2025. The study aims to demonstrate the drug's efficacy, safety, and target engagement through various assessments.
FAQ
What is the current stock price of Alterity Therapeutics (ATHE)?
What is the market cap of Alterity Therapeutics (ATHE)?
What does Alterity Therapeutics Limited specialize in?
What are the company's lead drug candidates?
Where is Alterity Therapeutics Limited based?
What was Alterity Therapeutics formerly known as?
What recent achievements has the company made?
Who is the CEO of Alterity Therapeutics Limited?
What is the financial condition of Alterity Therapeutics?
What does ATH434 target?
What does PBT2 target?
What type of collaborations is Alterity Therapeutics engaged in?
